ICU Medical, Inc. (NASDAQ:ICUI) Shares Bought by Citigroup Inc.

Citigroup Inc. grew its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 100.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,965 shares of the medical instruments supplier’s stock after purchasing an additional 14,512 shares during the period. Citigroup Inc. owned approximately 0.12% of ICU Medical worth $5,278,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC boosted its holdings in ICU Medical by 441.7% in the second quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock valued at $691,000 after purchasing an additional 4,744 shares during the last quarter. LMR Partners LLP purchased a new position in shares of ICU Medical during the 3rd quarter valued at approximately $3,884,000. Savant Capital LLC purchased a new position in shares of ICU Medical during the 2nd quarter valued at approximately $431,000. Boston Partners acquired a new stake in shares of ICU Medical during the first quarter worth approximately $790,000. Finally, First Eagle Investment Management LLC bought a new stake in shares of ICU Medical in the second quarter worth $3,479,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Stock Down 1.8 %

Shares of ICU Medical stock opened at $160.96 on Tuesday. The stock has a market capitalization of $3.94 billion, a price-to-earnings ratio of -36.42 and a beta of 0.66. ICU Medical, Inc. has a twelve month low of $83.26 and a twelve month high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The business’s 50 day simple moving average is $174.60 and its 200-day simple moving average is $147.67.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ICUI shares. Jefferies Financial Group assumed coverage on shares of ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective for the company. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Raymond James boosted their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. KeyCorp increased their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Insiders Place Their Bets

In other ICU Medical news, COO Christian B. Voigtlander sold 1,962 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $169.08, for a total transaction of $331,734.96. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $18,665,666.78. This trade represents a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,364 shares of company stock valued at $6,869,878 over the last three months. Company insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.